There are developments in the European Union’s vaccine strategy with two recent announcements.
The European Medicines Agency (EMA) announced on Monday 3 October that it had started a ‘rolling review’ of the Pfizer-BioNTech messenger RNA vaccineComirnaty against the original SARS-CoV-2 strain and the sub-variants of concern BA.4 and BA.5 (see EUROPE B13020A31) for use in children aged 5-11 years.
Furthermore, as the efficacy and safety of the two messenger RNA vaccines against...